ConductScience.org, home

Paper36077433

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.

Mossenta M and 4 others. Int J Mol Sci, 2022. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Papers, record 36077433. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36077433

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
1.2
iCite
Revised in PubMed
2025-07-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Drug Resistance
Glypicans
Humans
Nanotechnology
Therapies, Investigational

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
NAGoverno ItalianoPubMed

Source PubMed

Download CSV of grants

References189

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135785307Research on the Construction of Bispecific-Targeted Sustained-Release Drug-Delivery Microspheres and Their Function in Treatment of Hepatocellular Carcinoma.ACS Omega2022https://conductscience.org/library/papers/35785307PubMed
229719757Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations.Beilstein J Nanotechnol2018https://conductscience.org/library/papers/29719757PubMed
331953246Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.Cancer Immunol Res2020https://conductscience.org/library/papers/31953246PubMed
418505598Glypicans.Genome Biol2008https://conductscience.org/library/papers/18505598PubMed
531116141Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma.Clin Transl Gastroenterol2019https://conductscience.org/library/papers/31116141PubMed
631056726Epigenetics of hepatocellular carcinoma.Clin Transl Med2019https://conductscience.org/library/papers/31056726PubMed
718650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
818480006Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.Am J Clin Pathol2008https://conductscience.org/library/papers/18480006PubMed
929162156The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice.Eur J Med Res2017https://conductscience.org/library/papers/29162156PubMed
1030665869Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019https://conductscience.org/library/papers/30665869PubMed
1131954487Advances in molecular classification and precision oncology in hepatocellular carcinoma.J Hepatol2020https://conductscience.org/library/papers/31954487PubMed
1227074018Modeling of Hepatocytes Proliferation Isolated from Proximal and Distal Zones from Human Hepatocellular Carcinoma Lesion.PLoS One2016https://conductscience.org/library/papers/27074018PubMed
1331841768Towards the overcoming of anticancer drug resistance mediated by p53 mutations.Drug Resist Updat2020https://conductscience.org/library/papers/31841768PubMed
1411084048Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium.J Biol Chem2001https://conductscience.org/library/papers/11084048PubMed
1526341193Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.Drug Resist Updat2015https://conductscience.org/library/papers/26341193PubMed
1630061739Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/30061739PubMed
1729568237Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.Cancer Cell Int2018https://conductscience.org/library/papers/29568237PubMed
1825457975The folate receptor as a rational therapeutic target for personalized cancer treatment.Drug Resist Updat2014https://conductscience.org/library/papers/25457975PubMed
1934866166Nanoparticles for Cancer Therapy: Current Progress and Challenges.Nanoscale Res Lett2021https://conductscience.org/library/papers/34866166PubMed
2032127929Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma.J Cancer2020https://conductscience.org/library/papers/32127929PubMed

See all 189 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42182336Ablation of glypican-3 enhances radiosensitivity in liver cancer by prolonging G2/M arrest and activating the ATM/CHK2 pathway.bioRxiv2026https://conductscience.org/library/papers/42182336PubMed
41675547Emerging nanomedicine strategies for hepatocellular carcinoma therapy.IMetaOmics2024https://conductscience.org/library/papers/41675547PubMed
40722645Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines2025https://conductscience.org/library/papers/40722645PubMed
39660335Alpha-fetoprotein, glypican-3, and kininogen-1 as biomarkers for the diagnosis of hepatocellular carcinoma.Int J Clin Exp Pathol2024https://conductscience.org/library/papers/39660335PubMed
39011387Ultrasound-Responsive Nanodelivery System of GPC3-Targeting and Sonosensitizer for Visualized Hepatocellular Carcinoma Therapy.Int J Nanomedicine2024https://conductscience.org/library/papers/39011387PubMed
38882543Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System.Int J Nanomedicine2024https://conductscience.org/library/papers/38882543PubMed
38213137Study on the Mechanism of Notch Pathway Mediates the Role of Lenvatinib-resistant Hepatocellular Carcinoma Based on Organoids.Curr Mol Med2025https://conductscience.org/library/papers/38213137PubMed
37240286Advances in Immunotherapy and Innovative Therapeutic Approaches for Cancer Treatment: Editorial to the Special Issue "State-of-the-Art Molecular Oncology in Italy".Int J Mol Sci2023https://conductscience.org/library/papers/37240286PubMed
36559264Co-Delivery System of Curcumin and Colchicine Using Functionalized Mesoporous Silica Nanoparticles Promotes Anticancer and Apoptosis Effects.Pharmaceutics2022https://conductscience.org/library/papers/36559264PubMed
36499616Activated Hepatic Stellate Cells in Hepatocellular Carcinoma: Their Role as a Potential Target for Future Therapies.Int J Mol Sci2022https://conductscience.org/library/papers/36499616PubMed

Download CSV of cited by

Genes55

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ACE1636PubTator's text mininghttps://conductscience.org/library/genes/1636NCBI Gene
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
ASGR1432PubTator's text mininghttps://conductscience.org/library/genes/432NCBI Gene
CCND1595PubTator's text mininghttps://conductscience.org/library/genes/595NCBI Gene
CD24857124PubTator's text mininghttps://conductscience.org/library/genes/57124NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD44960PubTator's text mininghttps://conductscience.org/library/genes/960NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CEACAM31084PubTator's text mininghttps://conductscience.org/library/genes/1084NCBI Gene
CFAP52146845PubTator's text mininghttps://conductscience.org/library/genes/146845NCBI Gene
CLEC4D338339PubTator's text mininghttps://conductscience.org/library/genes/338339NCBI Gene
CTAG1A246100PubTator's text mininghttps://conductscience.org/library/genes/246100NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
CXADRP1653108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene
CYCS54205PubTator's text mininghttps://conductscience.org/library/genes/54205NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EPAS12034PubTator's text mininghttps://conductscience.org/library/genes/2034NCBI Gene

See all 55 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36077433

GET https://conductscience.org/api/papers/v1/36077433/references?page=2